SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: PaulW who wrote (4246)3/6/2000 6:29:00 PM
From: Biomaven  Respond to of 10280
 
Paul,

Merck's Singulair has been on the market for a while now, and this is just a pediatric dose formulation. It's been a pretty successful drug, growing fairly rapidly, with current sales of $500m and sales estimated to reach over $1.5 billion within the next three to four years.

Again this is used to treat chronic asthma, competing with steroids and Intal. I would bet that every person with a Singulair prescription also has an albuterol/Xopenex script. An individual's albuterol use should decline with successful treatment with steroids or Singulair, but it doesn't go away altogether.

Peter



To: PaulW who wrote (4246)3/6/2000 9:34:00 PM
From: LLCF  Read Replies (3) | Respond to of 10280
 
<Singulair(R) 4 Mg Tablet is Approved by FDA to Help
Control Asthma In Children Two to Five Years of Age>

Between Asthma and ADD [and derrivs] has anyone done studies as to whether there is truly an explosion of problems, or just more people treating problems that we and our parents also had??? I mean I can't believe the athma cases [#] I've seen in my daughters groups.... and the ritalin use in friends kids schools.

DAK


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News